# LUMINOSITY (NCT03539536)

> Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03539536
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Non-small Cell Lung Cancer
- Interventions: Telisotuzumab vedotin
- Enrollment: 270
- Primary outcome: Overall Response Rate (ORR) (Stage 1 and Stage 2)
- Primary outcome: Number of Participants with Adverse Events (Alternate dose cohort)

## Indexed commentary on LUMINOSITY so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 44
- YouTube: 33
- Podcasts: 27
- Bluesky threads: 3
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=luminosity-nct03539536

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03539536", "email": "<work email>"}; the inbox owner confirms by the emailed link.